Exosomes from the sera of EGFR-mutant NSCLC patients mediate the activation of mammalian targets of the PI3K/AKT/rapamycin (mTOR) pathway and induce invasion through upregulation of matrix metalloproteinase-9 in A549 cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.